Table 2.

Characteristics of PHEO/PGL in patients with ‘progressive’ disease according to RECIST.

Pt.	Tm.	TNL	Loc.	F/M	MUT	A/D	Sz	CES	SzLFU	CESLFU	Time	BC	Growth (%)
1	1	2/4	L	F	Pool	30	1.6	0 (A)	2.2	2 (S)	19	Neg	37.5
2	2	5/7	L	F	BF	37	1.3	1 (A)	2.8	2 (A)	28	Pos	115
3	3	1/4	R	M	BF	14	3.0	0 (A)	4.4	5 (S)	74	Pos	46.7
3	4	3/4	L	M	BF	25	1.0	0 (A)	1.6	2 (A)	15	Pos	60
3	5	4/4	PGL	M	BF	27	1.0	1 (A)	1.7	1 (A)	25	NA	70
4	6	1/3	Rcon	F	Pool	26	1.0	0 (A)	2.5	2 (A)	14	Pos	150
4	7	2/3	L	F	Pool	26	1.2	0 (A)	2.6	0 (A)	39	Pos	117
5	8	2/2	R	M	BF	37	0.6	2 (A)	2.8	0 (A)	51	Neg	367
6	9	1/1	B	F	Pool	69	3.0	0 (A)	4.1	NA (S)	20	Pos	36.7
	9.1		L				1.5		2.0				33.3
	9.2		R				1.0		1.4				40
	9.3		R				0.5		0.7				40
7	10	1/1	R	F	Pool	19	1.0	4 (S)	1.2	3 (S)	10	Pos	20

A/D, age at diagnosis; A/S, disease-related symptoms absent/present as documented; B, bilateral PHEO; BC, biochemical test result positive (Pos) or negative (Neg) for the respective tumour at any point in time in the course of the disease; BF, ’Black Forest’ mutation; CES, clinical evaluation score sum at diagnosis and at last follow-up (CESLFU) (asymptomatic ≤2.5, symptomatic ≥3.0, see also ’Results’ section) ; F/M, female/male gender; L, left-sided pheochromocytoma (PHEO) ; Loc, tumour location; MUT, underlying mutation; NA, not applicable; PGL, paraganglioma; Pool, other mutation; Pt, patient number; R, right-sided PHEO; Rcon, right-sided conglomerate tumour (2x) ; Sz, tumour size at diagnosis and at last follow-up (SzLFU) ; Time, time elapsed to last follow-up prior to surgery (months) ; Tm, tumour number; TNL, current tumour number in patients with multiple consecutive tumours.